Navigation Links
Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
Date:9/15/2010

pecializing in personalized medicine. Diaceutics mission is to build bridges between pharmaceutical and diagnostic companies and to provide pharmaceutical industry leaders with the foundation and operational structure necessary to effectively develop and commercialize targeted therapies that better meet patients' needs and improve return on investment. For more information, visit http://www.diaceutics.com.

About Pharmacogenetics:

Genetic differences between individuals mean that drug response rates are often variable across a population, and this has significant implications for healthcare cost effectiveness. Pharmocogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs. It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMA have recognised this in their Critical Path Initiative and Road Map respectively.

Contact for London Genetics Ltd: Dominique Kleyn, CEO, +44-(0)207-594-1838 Emma Palmer Foster, Strategic Communications Consultant, +44-(0)7880-787-185 communications@londongenetics.com Contact for Diaceutics: Mollie Roth, Esq., Chief Operating Officer +1-202-280-5887 mollie.roth@diaceutics.com
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
2. London Genetics Conference Proceedings Published in Drug Discovery Today
3. First Awards Made by London Genetics Proof-of-Concept Fund
4. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
5. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
6. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
7. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
8. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
9. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
10. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
11. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... PLAINS, N.Y., AUG. 2 Two major studies,published today ... doctors,better identify pregnant women at risk for preterm delivery ... Foundation said today. In one large multi-center trial ... (most of whom had no prior history of preterm ...
... - Access to Large Population of Glioblastoma Patients Expected ... Phase ll Study of Promising New Approach -, ... PPHM ), a clinical stage biopharmaceutical,company developing targeted monoclonal ... infection, today announced that the first,patient has been administered ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...
... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...
... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...
... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...
... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Mitral bioprosthesis is a portrait ... based on 25 years of ... makes it an excellent choice ... replacement--particularly elderly patients and those ...
Medicine Products: